BioCentury
ARTICLE | Clinical News

Innovent's PD-1 inhibitor leads to 68.4% ORR in Phase Ib for first-line NSCLC

September 21, 2018 4:38 PM UTC

Innovent Biologics Inc. (Suzhou, China) reported data from 19 evaluable patients with non-squamous non-small cell lung cancer (NSCLC) in cohort D of a Chinese Phase Ib trial showing that anti-PD-1 antibody sintilimab (IBI308) plus Alimta pemetrexed and cisplatin as first-line treatment led to an objective response rate (ORR) of 68.4%. Median duration of response, progression-free survival (PFS) and overall survival (OS) have not yet been reached as of a June 28 data cutoff. Data were presented at the Chinese Society of Clinical Oncology meeting in Xiamen.

The open-label trial is also evaluating sintilimab as monotherapy in patients with melanoma, advanced malignancies of the digestive system and NSCLC after failure of first-line therapy...